NSRX logo

NASUS PHARMA LTD

NSRXNYSE AMERICAN
🏆 #4666 by market capUS Equity
$3.39▼ $0.23 (−6.87%)
After hours · at close
🔔
Track NSRX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 6.9%
7d▼ 2.0%
14d▼ 5.0%
30d▼ 16.3%
ytd▼ 61.7%
1y▼ 55.7%
🏦Market Cap
$29M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$3.38 – $3.41
52-Week Range
$1.98 – $9.50
Volume
$2.12B
Avg Volume
$1.76B
Shares Outstanding
8.6M
Next Earnings
Nov 14, 2026

Fundamentals Snapshot

Annual Revenue
$3M
Last Q Revenue
$648,104
P/E Ratio
-3.3
P/S Ratio
0.0x
EPS (TTM)
$-0.99
Dividend Yield
0.00%

Why Investors Own NSRX

  • ✓High-growth profile — revenue up +37.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 28% gross margin and 29% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NSRX logo

NASUS PHARMA LTD

NSRX
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$3M▲ +40.8% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
28.0%▲ +2.9% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$680,336▲ +40.8% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$822,073▲ +40.8% YoY
StockOtter · stockotter.space

About NASUS PHARMA LTD

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$3.88
▲ +14.5% Upside
High Target$4.66
Low Target$3.42
Based on 14 analysts

Latest News & Updates

🚀
CNBC·2h ago

NASUS PHARMA LTD tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift NSRX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

NASUS PHARMA LTD announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.